The Impact of Tumor Size on Outcomes After Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
The Impact of Tumor Size on Outcomes After Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
复制标题
DOI：
10.1016/j.ijrobp.2013.08.020
复制
发表时间：
2013-12-01
影响因子：
7
通讯作者：
Cho, B. C. John
中科院分区：
文献类型：
--
作者：
Allibhai, Zishan;Taremi, Mojgan;Cho, B. C. John
目的：立体定向放射治疗医学上不能手术的早期非小细胞肺癌（NSCLC）提供了良好的控制率。大多数出版的系列主要涉及小型（通常= 3）肺炎发生率低，不受肿瘤或靶区大小的显著影响。目前采用的立体定向体部放射治疗剂量方案可以提供安全有效的局部治疗，即使是较大的孤立性NSCLC肿瘤（肿瘤直径高达5.7 cm或肿瘤体积高达100 cm（3））但与更多的非局部故障以及较差的存活率相关。这些观察结果表明，这些患者可能受益于更广泛的分期或考虑辅助治疗。(C)2013 Elsevier Inc.
Purpose: Stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC) offers excellent control rates. Most published series deal mainly with small (usually = 3 pneumonitis were low and not significantly affected by tumor or target size.Conclusions: Currently employed stereotactic body radiation therapy dose regimens can provide safe effective local therapy even for larger solitary NSCLC tumors (up to 5.7 cm in tumor diameter or 100 cm(3) in tumor volume) but are associated with more nonlocal failures as well as poorer survival. These observations suggest these patients may benefit from more extensive staging or consideration of adjuvant therapy. (C) 2013 Elsevier Inc.